

Notice of Allowability

Application No.

09/931,009

Examiner

Samuel W Liu

Applicant(s)

SMITH, THERESA H.

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 10-15-04.
2. ☒ The allowed claim(s) is/are 1-4.
3. ☒ The drawings filed on 17 August 2001 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 11/28/01 (revised on pages 3 & 4).
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

DETAILED ACTION

This Office action is in response to applicants' amendment filed 15 October 2004, which cancels claims 5-11 and amends claim 1. The stated amendment has been entered. Thus, the pending claims 1-4 are therefore examined in this Office action.

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than payment of the Issue Fee.

Amendments to the specification:

On page 4, lines 2 and 3 of [0006], change "(NSAID's)" and "(DMAD's)" to "(NSAIDs)" and "(DMADs)", respectively.

On page 7, line 2 of [0021], change "G-P-R-P" to "GPRP (SEQ ID NO:2); and line 2 of [0022], change "Gly-Pro-Arg-Pro (GPRP)" to "Gly-Pro-Arg-Pro (GPRP) (SEQ ID NO:2)".

On page 8, lines 4-5 of [0023], change "cleavage is Gly-Pro-Arg-Val (GPRV) and this peptide functions well as a polymerization inhibitor (Reference 25)" to "cleavage is tripeptide consisting of Gly-Pro-Arg or tetrapeptide comprising core sequence Gly-Pro-Arg, and this peptide functions well as a polymerization inhibitor (see page 1015 of Laudano et al. reference, i.e., Reference 25)". On page 8, line 6 of [0023], change "Gly-Pro-Arg-Pro" to "Gly-Pro-Arg-Pro (SEQ ID NO:2)", and line 12 of [0023], change "GPRP" to "GPRP (SEQ ID NO:2)". On page 8, the last line, change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 9, lines 6, 8, 12 and 14 of [0024] and lines 1 and 3 of [0025], change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 10, line 5 from the top and lines 1 and 3, change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 11, line 4 from the top and line 2 from the bottom, change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 12, lines 3 and 7, change "GPRP" to "GPRP (SEQ ID NO:2)".

Art Unit: 1653

On page 13, line 5 from the top and line 2 of [0029], change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 14, line 5, change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 15, line 17 of [0031], change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 16, line 4, change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 17, line 2 of [0033], lines 1, 9 and 12 of [0034], change "GPRP" to "GPRP (SEQ ID NO:2)". On page 17, line 2, change "GPAP" to "GPRP (SEQ ID NO:2)".

On page 18, line 5 from the top and line 1 of [0036], change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 19, line 3, change "H-Gly-Pro-Arg-Pro-OH" to "H-Gly-Pro-Arg-Pro-OH (SEQ ID NO:2 sequence); lines 4 and 6, change "GPRP" to "GPRP (SEQ ID NO:2)". On page 19, lines 1 and 2 of [0038], change "GPRP-OH" and "GPRP-NH₂" to "GPRP-OH (SEQ ID NO:2 sequence)" and "GPRP-NH₂ (SEQ ID NO:2 sequence)", respectively.


On page 22, line 5 from the top and line 2 of [0041], change "GPRP" to "GPRP (SEQ ID NO:2)".

On page 26, line 5 of [0047], change "GPRP" to "GPRP (SEQ ID NO:2)".

Conclusion: Claims 1-4 are allowable over the art of record.

Any comments considered necessary by applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Jon Weber, can be reached at (571) 272-0925. The official fax number for Technology Center 1600 is (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.


KAREN COCHRANE CARLSON, PH.D.
PRIMARY EXAMINER

Application/Control Number: 09/931,009

Page 4

Art Unit: 1653

A handwritten signature in black ink, appearing to read 'Saul' or 'Saul L', with a long horizontal stroke extending to the right.

Samuel W. Liu, Ph.D.

Art Unit 1653, Examiner

January 31, 2004